Helius Shares Positive PoNSTEP Study Results on PoNS Therapy for MS

Helius Shares Positive PoNSTEP Study Results on PoNS Therapy for MS

NEWTOWN, PA — Helius Medical Technologies, Inc. (NASDAQ: HSDT) announced encouraging results from its PoNSTEP study, presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The findings highlight the long-term benefits of PoNS Therapy for people with multiple sclerosis (MS), especially in improving gait deficits. The study demonstrated that adherence to PoNS Therapy is crucial for achieving and sustaining clinically…

Aetna Healthcare agrees to reimburse PoNS device for MS patients

Aetna Healthcare has agreed to reimburse Helius Medical Technologies’ PoNS device, short for Portable Neuromodulation Stimulator, which uses electrical stimulation to improve walking in people with multiple sclerosis (MS). The policy […] The post Aetna agrees to reimburse PoNS device for MS patients appeared first on Multiple Sclerosis News Today.